

Renumbered claims

Application No. 09/636,801
Reply to Office Action dated July 27, 2006

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-72. (Canceled)

¹
73. (Previously Presented) An isolated polypeptide comprising SEQ ID NO: 392.

74.-75. (Canceled)

²
76. (Currently Amended) An isolated polypeptide comprising ~~amino acid~~ residues ~~1-27~~ of SEQ ID NO: 392, or a variant thereof having at least 90% identity to SEQ ID NO: 392, wherein said polypeptide variant reacts with an antibody that specifically binds the polypeptide of SEQ ID NO: 392.

³
77. (Currently Amended) An isolated polypeptide comprising SEQ ID NO: 392 or a variant thereof containing only conservative amino acid substitutions and an amino acid sequence having at least 90% identity to SEQ ID NO: 392, wherein said ~~polypeptide variant~~ reacts with an antibody that specifically binds the polypeptide of SEQ ID NO: 392.

⁴
78. (Currently Amended) A fusion polypeptide comprising a polypeptide according to any one of claims ~~76-77~~ ²⁻³.

⁵
79. (Currently Amended) A composition comprising a polypeptide according to any one of claims ~~76-77~~ ²⁻³ and at least one physiologically acceptable excipient.

Application No. 09/636,801
Reply to Office Action dated July 27, 2006

⁶
~~80.~~ (Currently Amended) A composition comprising a polypeptide according to any one of claims ~~263-277~~²⁶³⁻²⁷⁷ and at least one adjuvant.

⁷
~~81.~~ (Previously Presented) The composition of claim ~~80~~⁶, wherein the adjuvant is selected from the group consisting of: an MPL, QS21 and AS-2.